Analysts' Actions: Akamai, Bristol-Myers, Eli Lilly, Merck, Pfizer

NEW YORK (TheStreet) -- RATINGS CHANGES

Akamai (AKAM) was initiated with an outperform rating at Robert Baird. Twelve-month price target is $71. Company is an industry leader that can benefit from multiple secular trends, Robert Baird said.

Biglari (BH) was downgraded to hold at TheStreet Ratings.

Bristol-Myers (BMY) was initiated with a hold rating at Deutsche Bank. Valuation call, based on a 12-month price target of $52, Deutsche BAnk said.

Eli Lilly (LLY) was initiated with a buy rating at Deutsche Bank. Twelve-month price target is $71. Company is poised to return to growth in the coming years, Deutsche Bank said.

Merck (MRK) was initiated with a hold rating at Deutsche Bank. Valuation call, based on a 12-month price target of $63, Deutsche Bank said.

Pfizer (PFE) was initiated with a buy rating at Deutsche Bank. Twelve-month price target is $34. Company has a strong financial position with attractive valuation and dividend, Deutsche Bank said.

Rent-A-Center (RCII) was upgraded at Canaccord Genuity to buy from hold. Twelve-month price target is $32. More flexible labor model should cut costs, Canaccord Genuity said.

United Continental (UAL) was upgraded to buy at TheStreet Ratings.

Waste Management (WM) was upgraded at Stifel Nicolaus to buy from hold. Twelve-month price target is $55. Company is cutting its workforce, but can continue to generate steady free cash flow, Stifel Nicolaus said.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.


TheStreet Ratings team rates LILLY (ELI) & CO as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate LILLY (ELI) & CO (LLY) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

You can view the full analysis from the report here: LLY Ratings Report


TheStreet Ratings team rates BRISTOL-MYERS SQUIBB CO as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate BRISTOL-MYERS SQUIBB CO (BMY) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, notable return on equity, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

You can view the full analysis from the report here: BMY Ratings Report

This article was written by a staff member of TheStreet.

More from Stocks

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat